Al-Rawi Natheer H, Kawas Sausan Al, Ani Muwaffaq Al, Alnuaimi Ahmed Sameer, El-Sayed Walid, Alrashdan Mohammad S
Department of Oral and Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, United Arab Emirates.
Department of ENT, Tawam Hospital, Al-Ain, United Arab Emirates.
Eur J Dent. 2023 Oct;17(4):1170-1178. doi: 10.1055/s-0042-1760301. Epub 2023 Jan 30.
The aim of this study was to determine the value of immune expression of p63 and cyclin D1 in the prediction of lymphovascular invasion (LVI) and perineural invasion (PNI) in oral squamous cell carcinoma (OSCC).
Clinical and histopathologic features of 65 subjects with histologically confirmed OSCC were collected. Tissue microarray blocks representing all subjects were prepared for the immunohistochemical quantification of the nuclear expression of p63 and cyclin D1 using immune ratio plugin of image J software. Image analysis was performed by two independent pathologists. Independent samples -test, analysis of variance, and receiver operating characteristic curve tests were used for statistical analysis. The level of significance was set at ≤ 0.05.
The optimum cutoff value for the prediction of LVI for p63 and cyclin D1 was found to be 100 and 93.2, respectively, while the optimum cutoff value for the prediction of PNI for p63 and cyclin D1 was found to be 95.9 and 94, respectively. p63 and cyclin D1 expression correlated with several clinicopathologic features of the studied population. p63 expression was a significant predictor of moderate/poorly differentiated OSCC compared with well-differentiated OSCC. A parallel combination of positive p63 and cyclin D1 increased the specificity of predicting LVI from 89.1% and 67.4% for either p63 or cyclin D1, respectively, to 93.5% with a positive predictive value of 92.5%. Similarly, the parallel combination of the two markers raised the specificity of predicting PNI from 70% and 77.5% for either p63 or cyclin D1, respectively, to 90% with a positive predictive value of 86.3%.
Combined overexpression of nuclear markers p63 and cyclin D1 can be considered as a valuable independent predictor of LVI and PNI, and hence tumor progression, in OSCC.
本研究旨在确定p63和细胞周期蛋白D1的免疫表达在预测口腔鳞状细胞癌(OSCC)的淋巴管侵犯(LVI)和神经周侵犯(PNI)中的价值。
收集65例经组织学确诊为OSCC患者的临床和组织病理学特征。制备代表所有受试者的组织微阵列块,使用Image J软件的免疫比率插件对p63和细胞周期蛋白D1的核表达进行免疫组织化学定量分析。由两名独立病理学家进行图像分析。采用独立样本t检验、方差分析和受试者工作特征曲线检验进行统计学分析。显著性水平设定为≤0.05。
p63和细胞周期蛋白D1预测LVI的最佳截断值分别为100和93.2,而p63和细胞周期蛋白D1预测PNI的最佳截断值分别为95.9和94。p63和细胞周期蛋白D1的表达与所研究人群的几个临床病理特征相关。与高分化OSCC相比,p63表达是中/低分化OSCC的显著预测指标。p63和细胞周期蛋白D1阳性的平行组合将预测LVI的特异性从p63或细胞周期蛋白D1单独时的89.1%和67.4%分别提高到93.5%,阳性预测值为92.5%。同样,这两种标志物的平行组合将预测PNI的特异性从p63或细胞周期蛋白D1单独时的70%和77.5%分别提高到90%,阳性预测值为86.3%。
核标志物p63和细胞周期蛋白D1的联合过表达可被视为OSCC中LVI和PNI以及肿瘤进展的有价值的独立预测指标。